ArticleEuropean journal of nuclear medicine and molecular imaging2026
FAP expression in deep and superficial endometriosis: Association with MRI and transvaginal ultrasound visibility.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeFibroblast activation protein (FAP) is expressed in the fibroinflammatory stroma of endometriosis, but its relationship to conventional imaging visibility is unknown. We evaluated FAP expression in deep endometriosis (DE) and superficial endometriosis (SE) and its relationship to lesion visibility on magnetic resonance imaging (MRI) and transvaginal ultrasound (TVUS).
methodsWe retrospectively analyzed specimens from DE (n = 13) and SE (n = 9) patients who underwent MRI and/or TVUS. FAP expression was assessed immunohistochemically using H-scores. Two abdominal radiologists independently graded the visibility of pathology-confirmed lesions on MRI and TVUS using a study-specific 0-3 scale, with N/A assigned when the lesion location was outside the available imaging field of view. H-scores were compared by phenotype and imaging visibility (lower [0-1] vs higher [2-3]) using nonparametric analyses.
resultsFAP expression did not differ significantly between DE and SE (median H-scores 170 vs 200, p= 0.738). Endometriosis showed substantial FAP expression, although H-scores were lower than colorectal adenocarcinoma controls (p < 0.05). On MRI, no lesions were assigned N/A; low-/high-visibility groups included 5/16 lesions for Reader 1 and 3/18 for Reader 2, with median H-scores of 220/170 for both readers (both p > 0.05). On TVUS, 1 and 2 lesions were assigned N/A for Readers 1 and 2, respectively; among evaluable lesions, low-/high-visibility groups included 2/10 and 1/10 lesions, with median H-scores of 48/165 and 20/160, respectively, limiting conclusions regarding visibility and FAP expression.
conclusionDE and SE showed substantial stromal FAP expression, including SE lesions poorly visible on conventional imaging. These findings provide a histopathological rationale for FAP-targeted imaging in endometriosis.
Indexed as
Identifiers
42758302What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.